Scottish Medicines Consortium (SMC)

In October 2014, Dymista® was approved by the Scottish Medicines Consortium (SMC) for use within NHS Scotland.2

Assessment based on a broad range of evidence

Members of the SMC committee consider a broad range of evidence when deciding which medicines should be approved for use by NHS Scotland. Decisions are made from a broad perspective by including wide mixture of backgrounds among committee members, from clinicians – most of whom have a direct role in patient care – to three volunteer public partners, who ensure the views of the Scottish public are represented.2


Dymista® bottle

Indication under review: for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

For patients in whom the combination of azelastine hydrochloride and fluticasone propionate nasal spray is an appropriate choice of therapy, Dymista® provides the two ingredients in a single nasal spray.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of Dymista®. This SMC advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.


The website you are trying to access is designed for healthcare professionals in the UK, the content is not designed for the general public.

Are you a UK healthcare professional?